| Item | Cat. No. | Application | Isotype |
| Anti-IGHE mAbs [Ligelizumab Biosimilar] (MABL-4872) | MABL-4872 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IAP/CD47 mAbs [Ligufalimab Biosimilar] (MABL-4873) | MABL-4873 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-CD37 mAbs [Lilotomab Biosimilar] (MABL-4874) | MABL-4874 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-TGFB1 mAbs [Linavonkibart Biosimilar] (MABL-4875) | MABL-4875 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-LY6G6D/G6D/NG25/LY6-D/MEGT1/C6orf23;CD3E mAbs [Linclatamig Biosimilar] (MABL-4876) | MABL-4876 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa;Kappa |
| Anti-SIGLEC3/CD33/p67 mAbs [Lintuzumab Biosimilar] (MABL-4877) | MABL-4877 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E mAbs [Linvoseltamab Biosimilar] (MABL-4878) | MABL-4878 | ELISA, FACS, Functional assay, in vivo binding | G4;G4, Kappa;Kappa |
| Anti-Zaire Ebolavirus Glycoprotein mAbs [Larcaviximab Biosimilar] (MABL-4846) | MABL-4846 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL5 mAbs [Lasrekibart Biosimilar] (MABL-4847) | MABL-4847 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDCD1/CD279/PD1 mAbs [Latikafusp Biosimilar] (MABL-4848) | MABL-4848 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-SORT1/Gp95/NT3 mAbs [Latozinemab Biosimilar] (MABL-4849) | MABL-4849 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-SLC39A6/ZIP6 mAbs [Laventatug Biosimilar] (MABL-4850) | MABL-4850 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL13 mAbs [Lebrikizumab Biosimilar] (MABL-4851) | MABL-4851 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-APP mAbs [Lecanemab Biosimilar] (MABL-4852) | MABL-4852 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL17A&IL17F mAbs [Lecankitug Biosimilar] (MABL-4853) | MABL-4853 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-NT5E/CALJA/CD73;PDCD1/CD279/PD1 mAbs [Ledostomig Biosimilar] (MABL-4854) | MABL-4854 | ELISA, FACS, Functional assay, in vivo binding | G1;na, Kappa;Kappa |
| Anti-NCA90/p95 mAbs [Lemalesomab Biosimilar] (MABL-4855) | MABL-4855 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IAP/CD47 mAbs [Lemzoparlimab Biosimilar] (MABL-4856) | MABL-4856 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-Hepatitis B Virus mAbs [Lenvervimab Biosimilar] (MABL-4857) | MABL-4857 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-CSF2 mAbs [Lenzilumab Biosimilar] (MABL-4858) | MABL-4858 | ELISA, FACS, Functional assay, in vivo binding | Lenzilumab, Lenzilumab |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
